Natural product-based therapy for pulmonary arterial hypertension: Dehydroabietic acid inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 17/May/2015, 23.43

Regenerative therapy for DM: MiRNA-205 increases insulin-secreting cell mass and function via down regulation of its target genes, 17/May/2015, 23.23
May 17, 2015
Small molecule-based therapy for DM: AICAR, an analog of AMP, lowers hepatic glucose production and plasma glucose levels via up regulation of its target gene, 18/May/2015, 10.18 am
May 18, 2015
Show all

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for pulmonary arterial hypertension: Dehydroabietic acid inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3. 

Significance:  Dehydroabietic acid, by increasing the expression of their target gene, it may decrease the expression of Notch3. Thus, pharmacological formulations encompassing Dehydroabietic acid or its analogues” may be used to treat pulmonary arterial hypertension.

Undisclosed information: How Dehydroabietic acid decreases the expression of Notch3 

Idea Proposed/Formulated byDr L Boominathan Ph.D.


Terms & Conditions apply

To citeBoominathan, Natural product-based therapy for pulmonary arterial hypertension: Dehydroabietic acid inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 17/May/2015,  23.42,  Genome-2-Bio-Medicine Discovery center (GBMD),

Comments are closed.